Relation Between Amoxicillin Concentration in Sputum of COPD Patients and Length of Hospitalization

REFERENCES

• Wilson R. Bacterial infection and chronic obstructive pulmonary disease. Eur Respir J 1999 February; 13(2):233–235.
   PubMed Web of Science ®Google Scholar
• Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995 March 22; 273(12):957–960.
   PubMed Web of Science ®Google Scholar
• Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010 January 15; 181(2):150–157.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196–204.
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992 June; 36(6):1176–1180.
   PubMed Web of Science ®Google Scholar
• Fraschini F, Scaglione F, Falchi M, Dugnani S, Mezzetti M, Cicchetti F, Alfano G, Pintucci GP. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990 June; 2(3):171–177.
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992 June; 36(6):1171–1175.
   PubMed Web of Science ®Google Scholar
• Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981 January; 3(1):67–73.
   PubMedGoogle Scholar
• Neu HC. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med 1985 November 29; 79(5B):2–12.
   Web of Science ®Google Scholar
• Wallace RJ, Jr., Steele LC, Brooks DL, Luman JI, Wilson RW, McLarty JW. Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis. Antimicrob Agents Chemother 1985 June; 27(6):912–915.
   PubMed Web of Science ®Google Scholar
• Maesen FP, Davies BI, Baur C. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis. J Antimicrob Chemother 1987 March; 19(3):373–383.
   PubMed Web of Science ®Google Scholar
• Havard CW, Fernando A, Brumfitt W, Hamilton-Miller JM. A pilot study of ‘Augmentin’ in lower respiratory tract infections: pharmacokinetic and clinical results. Br J Dis Chest 1982 July; 76(3):255–260.
   PubMedGoogle Scholar
• Ingold A. Sputum and serum levels of amoxycillin in chronic bronchial infections. Br J Dis Chest 1975 July; 69:211–216.
   PubMedGoogle Scholar
• Lovering AM, Pycock CJ, Harvey JE, Reeves DS. The pharmacokinetics and sputum penetration of ampicillin and amoxycillin following simultaneous i.v. administration. J Antimicrob Chemother 1990 March; 25(3):385–392.
   PubMed Web of Science ®Google Scholar
• Hill SL, Burnett D, Lovering AL, Stockley RA. Use of an enzyme-linked immunosorbent assay to assess penetration of amoxicillin into lung secretions. Antimicrob Agents Chemother 1992 July; 36(7):1545–1552.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001 April; 163(5):1256–1276.
   PubMedGoogle Scholar
• Isenberg HD. Clinical Microbiology Procedures Handbook. 2004. Herndon, VA: American Society for Microbiology.
   Google Scholar
• Van Der Valk P, Monninkhof E, Van Der Palen J., Zielhuis G, van Herwaarden C., Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2004 October 1; 39(7):980–986.
   PubMed Web of Science ®Google Scholar
• Braude AC, Cohen RD, Penner JL, Preston MA, Rebuck AS. Pulmonary disposition of moxalactam. Chest 1984 December; 86(6):881–883.
   PubMed Web of Science ®Google Scholar
• Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981 September; 8(3):171–174.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, Muller C, Struck J, Muller B, Tamm M. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007 April; 131(4):1058–1067.
   PubMed Web of Science ®Google Scholar
• Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000 June; 117(6):1638–1645.
   PubMed Web of Science ®Google Scholar
• Weis N, Almdal T. C-reactive protein—Can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med 2006 March; 17(2):88–91.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006 January; 61(1):23–28.
   PubMed Web of Science ®Google Scholar
• O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007 July; 61(7):1112–1120.
   PubMed Web of Science ®Google Scholar
• Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995 September; 8(9):1594–1604.
   PubMed Web of Science ®Google Scholar
• Rubin BK. Other medications for aerosol delivery. Paediatr Respir Rev 2006; 7 Suppl 1:S76–S79.
   PubMedGoogle Scholar